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Objective: To generate insights into the mechanism of NVP induced hepatotoxicity.
Methods: Liver (HepG2) cells were cultured with various concentrations of NVP. This
cell line was chosen because it has low expression of cytochrome P450, allowing eval-
uation of the effects of NVP rather than speciﬁc metabolites. Cytotoxicity was determined
using a proliferation assay and cell numbers were monitored using trypan blue exclusion
assay for long term culture experiments and apoptosis induction was determined by
morphological and biochemical investigation.
Results: HepG2 cells treated with the highest concentration of NVP tested (819 mM)
initially showed a rounded morphology and all cells had died by week three of exposure.
Nuclear condensation and fragmentation, increased Annexin V/propidium iodide staining
and caspase 9 activation all supported the induction of apoptosis in HepG2 cells in
response to NVP treatment.
Conclusions: There is a clear induction of apoptosis in response to NVP which suggests
that NVP has signiﬁcant cytotoxicity, over and above any cytotoxicity of metabolites and
may contribute directly to patient hepatotoxicity.1. Introduction
Nevirapine (NVP) is classiﬁed as a non-Nucleoside Reverse
Transcriptase Inhibitor (NNRTI) and is frequently used in
combination with other antiretroviral drugs for the treatment of
HIV infections in resource limited settings [1]. NNRTIs bind
near the catalytic site of reverse transcriptase and limit the
ability of the enzyme to change conformation, resulting in
increased enzyme rigidity and inhibiting the polymerization
function of the enzyme [2]. However, the main drawback to
the use of NVP is the high risk of hepatotoxicity, and NVPinduced hepatotoxicity remains poorly understood. NVP-
associated liver toxicity is believed to occur into two main
ways. The ﬁrst is a drug hypersensitivity reaction or immune-
mediated mechanism typically occurring within the ﬁrst 6–12
weeks of treatment and is associated with elevation of trans-
aminases and skin reactions [3]. The second mechanism of NVP-
related liver toxicity typically has a delayed onset occurring
some 4–5 months after start of the treatment [4] and it was shown
that NVP has a greater association with hepatotoxicity than a
similar NNRTI, efavirenz [4].
For acute toxicity, in humans NVP undergoes cytochrome
P450-mediated oxidation to 2-, 3-, 8- and 12-hydroxy-nevirapine
(12-OH-NVP) which subsequently undergo glucuronidation fol-
lowed by excretion [5]. Animal model studies have suggested that
12-OH-NVP (formed by oxidation of an exocyclic methyl group)
can directly induce a skin rash, while the further metabolite
quinone methide (either produced directly from a benzylic free
radical intermediate in the generation of 12-OH-NVP or via sul-
fation to generate a 12-sulfoxy-NVP intermediate and subsequent
desulfation) can induce both the skin rash and hepatotoxicityrticle under the CC BY-NC-ND license (http://
Figure 1. Cytotoxicity of nevirapine to HepG2 cells as assessed by MTS
assays after 24 h of exposure. Experiment was conducted independently in
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sulfoxy-NVP is able to form speciﬁc covalently linked protein
adducts. Using the synthetic model electrophile 12-mesyloxy-
NVP, a number of sites of modiﬁcation of human serum albumin
and hemoglobin were identiﬁed [7], and stable hemoglobin NVP
adducts were detected in 12 out of 13 samples from HIV patients
undergoing antiretroviral NVP therapy [8].
While the mechanism remains incompletely known, it has
been proposed that the covalent binding of NVP to liver cell
proteins may induce cell death through apoptosis and necrosis
[9]. This is supported by studies that show mitochondrial
depolarization of lymphocytes in HIV-1 infected patients un-
dergoing NVP treatment [10]. While studies have consistently
shown a reduction in cell proliferation and modulation of the
cell cycle in response to NVP treatment, some authors have
suggested an increase in differentiation [11], while others have
proposed that there is an increase in cell senescence [12].
Given the widespread use of NVP, and the signiﬁcant risk of
hepatotoxicity, this study sought to investigate the
mechanism of NVP induced hepatotoxicity in long term
treatment. We postulated that long term treatment causes an
accumulation of NVP-free form over the ability of phase I
enzymes to combat, as in patient who develop liver toxicity
after long term treatment with NVP. To explore this HepG2
cells were chosen as the model cell in this study as they are
highly differentiated and have many features of normal liver
cells and these cells have been used by others to investigate the
mechanism of NVP induced hepatotoxicity [13]. Signiﬁcantly
however, HepG2 cells have low levels of phase I and phase
II enzymes [14] allowing dissection of the direct effect of
NVP on liver cells.
2. Materials and methods
2.1. Cultivation of HepG2, NVP treatment and cell
viability assays
The HepG2 cell line was acquired from ATCC (ATCC-
Number HB-8065) and cells were maintained in Dulbecco's
modiﬁed Eagle's medium (DMEM) supplemented with 10% heat
inactivated fetal bovine serum (FBS), 100 U/mL penicillin and
100 mg/mL streptomycin in a tissue culture ﬂask at 37 C in 5%
CO2. NVP (Sigma, St. Louis, MO) was made up as a 0.273 M
stock in DMSO. To determine the IC50 for NVP cells were
incubated with various concentrations of NVP for 24 h before
analysis of cell viability using the CellTiter 96® Aqueous One
Solution Cell Proliferation assay (MTS, Promega, WI) according
to the manufacturer's recommendations. For long term culture
experiments cells were incubated in the presence or absence
(control) of NVP with replacement of the medium twice a week.
Once a week the cells were trypsinized, counted by trypan blue
dye exclusion assay and further cultured as a 1:3 dilution. All
experiments were conducted independently in triplicate.
2.2. Confocal microscopy
HepG2 cells were grown to 80% conﬂuence on 12-mm
coverslips under standard conditions for 24 h. The cells cul-
ture medium was removed and then washed with PBS. The cells
were incubated with and without NVP (3, 30.3, 91 and 819 mM)
with media replacement (with or without NVP as appropriate) onday 4 of culture. The coverslips were collected at day 7.
Moreover, the ﬂoating (detached) cells were collected on days 4
and 7 by centrifugation using cytospin column as described
elsewhere [15]. The cells were ﬁxed with 100% ice-cold meth-
anol at room temperature for 15 min followed by washing two
times with PBS. The cells were permeabilized with 0.3% Triton
X-100/PBS for 10 min in humidiﬁed chamber and then washed
twice with 0.03% Triton X-100/PBS at room temperature with
gentle agitation. The cells were incubated with a 1:250 dilution
of DAPI diluted in PBS at room temperature and dark in hu-
midiﬁed chamber for 1 h follow by washing six times with
0.03% Triton X-100/PBS. The coverslips were mounted onto
glass slides using Prolong® Gold antifade reagent (Invitrogen)
before visualization under an Olympus FluoView 1000
(Olympus Corporation, Shinjuku-ku, Tokyo) with a 60× objec-
tive lens and equipped with Olympus FluoView Software v. 1.6.
2.3. Western blot analysis
HepG2 cells were cultured under standard conditions with or
without nevirapine as appropriate. On day 7 treatment, the cul-
ture medium was discarded and the cells were washed with
cooled PBS and lysed with RIPA buffer (1% Nonidet P-40,
0.5% sodium deoxycholate, 0.1% SDS in PBS). The cell lysates
were incubated on ice for 30 min with periodic mixing and
sonicated twice at 4 C for 5 min before centrifugation at
10000 ×g for 10 min after which supernatants were collected.
Proteins were quantiﬁed by the Bradford assay and stored
at −80 C until use. A total of 20 mg of total proteins were
separated by electrophoresis through a 12% SDS poly-
acrylamide gel and transferred to a nitrocellulose membrane by
electroblotting. The membrane was incubated with a 1:1000
dilution of an anti-human caspase 9 rabbit polyclonal antibody
(Cell Signaling Technology, Danvers, MA) followed by a
1:8000 dilution of a HRP-conjugated goat anti-rabbit IgG
polyclonal antibody (Thermo Fisher Scientiﬁc Inc., Rockford
IL). The membrane was subsequently re-probed with a 1:1000
dilution of an anti-human GAPDH mouse monoclonal antibody
(Santa Cruz Biotechnology, Inc. Santa Cruz, CA) followed by a
1:5000 dilution of a HRP-conjugated goat anti mouse IgG
polyclonal antibody (Sigma–Aldrich Co. Saint-Louis, MO).
Signal was recorded by an Azure Biosystems c400 quantitative
western blot imaging system (Azure Biosystems, Dublin, CA).triplicate. Error bars show S.D.
Figure 2. The 6-week cytotoxicity proﬁle of nevirapine in HepG2 cells.
The cells were treated with different concentration of the compound and are
counted once a week by means of the trypan blue dye exclusion assay. The
control cells were treated with 0.3% DMSO. The results are expressed as a
percentage of the control.
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Control and nevirapine treated cells were collected on day 7
and washed with ice-cold PBS and resuspended in binding
buffer (BD, Franklin Lakes, NJ), followed by double stainingFigure 3. Cell morphology of control (0.3 mM DMSO) and treated (819 mM
Olympus light microscope with magniﬁcation ×200.with the addition of 50 mg/mL FITC-conjugated Annexin V and
20 mg/mL propidium iodide. After 15 min, the cells were
analyzed by ﬂow cytometry on a FACSCalibur cytometer (BD
Biosciences, San Jose, CA) using CELLQuest™ software.
2.5. Data analysis
IC50 curves were generated using the program GraphPad Prism
version 5.0. Percent survival (Y axis) versus log concentration of
nevirapine (X axis) was plotted. The IC50 was calculated by the
software. Each experiment was done independently in triplicate
with duplicate analysis. The graphs of 6-week cytotoxicity proﬁles
of NVP inHepG2 cells were plotted usingGraphPad Prism version
5.0. Percent survival (Y axis) was calculated in percent of the
control versus time (X axis) was plotted.
3. Results
3.1. IC50 of NVP in HepG2 cells
To determine the IC50 of NVP, 4 × 10
3 HepG2 cells were
incubated in wells of a 96 well plate with 50–3000 mM NVP for
24 h under standard conditions after which cell viability was
determined using the CellTiter 96® AQueous One Solution Cell
Proliferation Assay. Experiment was undertaken independentlyNVP) HepG2 cells over three weeks of treatment as observed under an
Figure 4. Nuclear morphology of control (0.3% and 5% DMSO) and NVP treated (at concentration indicated) HepG2 cells.
(A) Floating cells collected on day 4 of treatment (B) ﬂoating cells collected on day 7 of treatment and (C) attached cells collected on day 7 of treatment.
Cells were stained with DAPI and observed under an Olympus FluoView 1000 confocal microscope at magniﬁcation ×60.
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Figure 5. Analysis of Annexin V/propidium iodide staining of control and NVP treated HepG2 cells. Cells were not treated (control) or treated with NVP
(819 mM) for one week before analysis by ﬂow cytometery after staining with Annexin V and propidium iodide.
(A, B) representative scatter plots for untreated (control) and treated (NVP) cells. (C, D) tabulation of (C) Annexin V positive and (D) apoptotic cells from
three independent experiments. CO: Control, NVP: nevirapine treated cells. * P < 0.05.
Figure 6. Western blot analysis of (pro)caspase 9 activation.
HepG2 cells were treated with a range of concentrations of NVP as indi-
cated or not treated (mock) or treated with vehicle only (0.3% DMSO) and
on day 7 post treatment cells were investigated for (pro)caspase 9 expres-
sion by western blot. Signal for cleaved (active) caspase 9 was quantitated
by Image J densitometry and plotted for three independent experiments.
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viability in a dose-dependent manner (Figure 1), and the IC50 of
NVP at 24 h was calculated as 818.975 ± 88.99 mM, a value
lower than that previously reported for 24 h, but in very close
agreement with the value of 814 mM reported at 48 h in a pre-
vious study [13].
3.2. Long term culture of HepG2 cells with NVP
To determine the long term effects of NVP treatment, HepG2
cells were plated at a density of 4 × 106 cells in T25-cm2 ﬂasks
and after 16–18 h the complete medium was removed. The
control ﬂasks were reﬁlled with complete medium containing
0.3% DMSO whereas the remaining ﬂasks were ﬁlled complete
medium containing NVP at six different concentrations (819,
273, 91, 30.3, 10.1 and 3.3 mM). Cells were cultured for 6
weeks with replacement of the medium every 3days and sub-
culture every 7 days. Cell numbers were counted weekly using
the trypan blue exclusion assay. Results, calculated as a per-
centage of control cells are shown in Figure 2. Cells treated with
highest concentration of NVP (819 mM) initially showed a
rounded cell morphology with cells detaching from week one
and by week three, all cells had died (Figure 3). Some growth*denotes statistically signiﬁcant difference, P < 0.05.
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mately normal at lower conditions, and no changes in cell
morphology was seen when cells were cultured at 273 mM or
lower concentrations.
3.3. Induction of apoptosis by NVP
The rounding and detachment of the cells treated with the
highest level of NVP is a classic hallmark of the induction of
cellular apoptosis [16]. To further investigate this, cells were
again treated, or not treated for one week with NVP at a
range of concentrations. On day 4 any detached cells were
collected and on day 7 both detached and attached cells were
collected. Cells were stained with DAPI, and investigated
under a confocal microscope. Results (Figure 4) show clear
chromosome condensation and nuclear fragmentation in
ﬂoating cells from day 4 on. Nuclear fragmentation can be seen
in ﬂoating cells from day 4 at concentrations as low as
30.3 mM, and evidence of nuclear fragmentation is abundant at
the highest concentration examined (819 mM). On day 7 some
evidence of nuclear condensation in detached cells can be seen
even with the lowest concentration examined (3.3 mM,
Figure 4). Day 7 attached cells show evidence of altered nu-
clear morphology in cells treated at the highest concentration
(819 mM) and in cells treated with 5% DMSO as a positive
control.
To further characterize the induction of apoptosis in response
to NVP treatment, cells were treated with the highest concen-
tration of NVP (819 mM) or not treated for 1week, after which
the cells were collected and assayed by staining with Annexin V/
propidium iodide and assayed by ﬂow cytometry. Results
(Figure 5) show the clear induction of apoptosis, with a high
proportion of cells showing positive staining with both Annexin
V and propidium iodide (Figure 6).
Cellular rounding and detachment, nuclear condensation and
fragmentation and positive Annexin V/PI staining are all
considered classic markers of the induction of apoptosis [17]. To
provide further evidence of the induction of apoptosis, cells were
again treated with a range of NVP concentration or not treated,
and cells examined for activation of caspase 9 by western
blotting. Results show an increase in the presence of the
active, cleaved form of caspase 9. The reduction of procaspase
9 and increase of cleaved caspase 9 were both statistically
signiﬁcant at the highest concentration used (819 mM), but the
results were broadly consistent with a dose-dependent increase
in caspase 9 processing.
4. Discussion
NVP is a widely used antiretroviral drug in resource poor
setting, but the mechanism by which NVP induces hepatotoxicity
remains to be clearly established, and moreover how NVP can
induce both an early [3] and a late [4] reaction similarly remains
unexplained. Current models suggest that the early reaction is
at least in part an idiosyncratic drug reaction mediated by an
immune response against intermediate metabolites of NVP [18].
By utilizing HepG2 cells, which have low expression of phase
I and phase II enzymes we have been able to produce the ﬁrst
evidence that NVP in itself, and not its reactive metabolites,
may contribute directly towards long term treatment associated
hepatotoxicity through the induction of apoptosis.The proposal that NVP induces speciﬁc effects is supported
by a previous study that showed that liver cells treated with NVP
undergo either G2/M or G1/G0 phase arrest. Using HepG2 and
THLE2 cells Fang and Beland [13] proposed that the stage of cell
arrest was correlated with the basal level of p53 in the cell line
investigated, and that THLE2 cells which show high levels of
p53 arrested in G1/G0, while in their hands HepG2 showed
low levels of p53 and arrested in G2/M. However, we have
previously demonstrated robust levels of p53 in HepG2 [17],
and while Fang and Beland show no increase of p53 protein
level or activating phosphorylation [13], other authors have
shown signiﬁcantly increased expression levels of p53 and
p21 in Hela cells [12]. While cell cycle arrest is a common
occurrence after DNA damage there is no evidence to suggest
that NVP is directly genotoxic [19].
In their study, Fang and Beland [13] proposed that apoptosis
was not the cause of the cell deﬁcit seen in HepG2 cells treated
with NVP. However, in this study we have clearly shown
through multiple morphologic and biochemical methods that
NVP induces apoptosis in HepG2 cells. Apoptosis in
mammalian cells is induced through one of two main
pathways, and extrinsic signaling mechanism governed by the
activation of a death receptor and subsequent activation of
caspase 8, and an intrinsic pathway governed by mitochondria
and the activation of caspase 9 [20]. As shown here, caspase 9
is activated in the apoptotic process, showing that this is an
intrinsic activation of apoptosis.
Of particular concern is the evidence that shows that even
low levels of NVP treatment were associated with the induction
of apoptosis. Raised levels of cleaved caspase 9 were seen at
concentrations as low as 30.3 mM, and evidence of nuclear
condensation can be seen with treatment after 7 days with as
little as 3.3 mM. These results suggest that there is no clear
threshold below which NVP has no effect. This would be
consistent with reports of hepatotoxicity in HIV/HCV patients
with blood levels of NVP as low as 22.5 mM [21]. Overall, our
results suggest that NVP induced hepatotoxicity may results
from direct consequences of NVP administration, and not only
through idiopathic effects as has been suggested by others [18].
Further studies will help elucidate the mechanism of NVP
induced hepatotoxicity.Conﬂict of interest statement
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